Glimzab M Forte 1mg/1000mg Tablet is a combination oral antidiabetic medication containing Glimepiride 1mg and Metformin 1000mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, functions by stimulating pancreatic beta cells to enhance insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, improving peripheral insulin sensitivity, and enhancing glucose uptake in muscle tissues. This dual mechanism provides effective glycemic control in patients inadequately managed by diet and exercise alone or those requiring combination therapy. Glimzab M Forte is typically prescribed when monotherapy with either agent is insufficient. It is essential to monitor renal function before and during treatment due to the risk of lactic acidosis associated with Metformin, especially in patients with impaired renal function or other contraindications. Common adverse effects may include gastrointestinal disturbances such as nausea, vomiting, diarrhea, and hypoglycemia, particularly due to Glimepiride. Dose adjustments and lifestyle modifications should be considered to optimize therapeutic outcomes. This medication should be used under medical supervision with regular monitoring of blood glucose levels, renal function, and overall metabolic status to ensure safety and efficacy.